Laurencin CT, et al. Tissue engineering: orthopedic applications. Annu Rev Biomed Eng. 1999;1:19–46.

Article  CAS  PubMed  Google Scholar 

Laurencin C, Khan Y, El-Amin SF. Bone graft substitutes. Expert Rev Med Devices. 2006;3(1):49–57.

Article  CAS  PubMed  Google Scholar 

Amini AR, Wallace JS, Nukavarapu SP. Short-term and long-term effects of orthopedic biodegradable implants. J long Term Eff Med Implants. 2011;21(2):93–122.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amin S, et al. Trends in fracture incidence: a population-based study over 20 years. J Bone Min Res. 2014;29(3):581–9.

Article  Google Scholar 

Hootman JM, et al. Updated projected prevalence of Self-Reported Doctor-Diagnosed arthritis and arthritis-Attributable activity limitation among US adults, 2015–2040. Arthritis Rheumatol. 2016;68(7):1582–7.

Article  PubMed  PubMed Central  Google Scholar 

Amin U, et al. An overview of the management of osteoporosis in the aging female population. Womens Health (Lond). 2023;19:17455057231176655.

Article  CAS  PubMed  Google Scholar 

Michou L, et al. Prevalence and incidence of paget’s disease of bone: Temporal trend over 20 years in the Province of quebec, Canada. Bone. 2023;176:116895.

Article  PubMed  Google Scholar 

Yu H, et al. Pathogenic mechanisms of osteogenesis imperfecta, evidence for classification. Orphanet J Rare Dis. 2023;18(1):234.

Article  PubMed  PubMed Central  Google Scholar 

Chan E, DeVile C, Ratnamma VS. Osteogenesis imperfecta. BJA Educ. 2023;23(5):182–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kehoe T, Blind E, Janssen H. Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspective. Br J Clin Pharmacol. 2019;85(6):1208–12.

Article  PubMed  Google Scholar 

Migliorini F, et al. Pharmacological agents for bone fracture healing: talking points from recent clinical trials. Expert Opin Investig Drugs. 2023;32(9):855–65.

Article  CAS  PubMed  Google Scholar 

Liu Z, et al. Overview of physical and Pharmacological therapy in enhancing bone regeneration formation during distraction osteogenesis. Front Cell Dev Biol. 2022;10:837430.

Article  PubMed  PubMed Central  Google Scholar 

Rocha VMD, et al. Use of bisphosphonates, calcium and vitamin D for bone demineralization in patients with human immunodeficiency virus/acquired immune deficiency syndrome: A systematic review and Meta-Analysis of clinical trials. J Bone Metab. 2020;27(3):175–86.

Article  PubMed  PubMed Central  Google Scholar 

Holstein SA. A patent review of bisphosphonates in treating bone disease. Expert Opin Ther Pat. 2019;29(5):315–25.

Article  CAS  PubMed  Google Scholar 

Ringe JD, Body JJ. A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover. Clin Exp Rheumatol. 2007;25(5):766–74.

CAS  PubMed  Google Scholar 

Bauer DC. Review: human parathyroid hormone reduces fractures and increases bone mineral density in severe osteoporosis. ACP J Club. 2006;145(3):71.

Article  PubMed  Google Scholar 

Gallacher SJ, Dixon T. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int. 2010;87(6):469–84.

Article  CAS  PubMed  Google Scholar 

Kim KM, Lee SY, Rhee Y. Influence of dosing interval and administration on the bone metabolism, skeletal effects, and clinical efficacy of parathyroid hormone in treating osteoporosis: A narrative review. JBMR Plus. 2017;1(1):36–45.

Article  PubMed  PubMed Central  Google Scholar 

Bjarnason NH, et al. Adverse bone effects during Pharmacological breast cancer therapy. Acta Oncol. 2008;47(4):747–54.

Article  CAS  PubMed  Google Scholar 

Boehm E et al. Real-life effects of Pharmacological osteoporosis treatments on bone mineral density by quantitative computed tomography. J Bone Min Metab, 2024.

Lin JH. Bisphosphonates: a review of their Pharmacokinetic properties. Bone. 1996;18(2):75–85.

Article  CAS  PubMed  Google Scholar 

Aoki K, et al. Peptide-based delivery to bone. Adv Drug Deliv Rev. 2012;64(12):1220–38.

Article  CAS  PubMed  Google Scholar 

Carbone EJ, et al. Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties. Nanomedicine. 2017;13(1):37–47.

Article  CAS  PubMed  Google Scholar 

Gu W, et al. Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration. Int J Nanomed. 2013;8:2305–17.

Article  Google Scholar 

Caraglia M, Santini D. Target therapy of bone metastases and tumours. Curr Cancer Drug Targets. 2009;9(7):789–90.

Article  CAS  PubMed  Google Scholar 

Ogawa K, Washiyama K. Bone target radiotracers for palliative therapy of bone metastases. Curr Med Chem. 2012;19(20):3290–300.

Article  CAS  PubMed  Google Scholar 

Rolfo C, et al. Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. Expert Opin Biol Ther. 2014;14(1):15–26.

Article  CAS  PubMed  Google Scholar 

Sonoda S, Yamaza T. A new target of dental Pulp-Derived stem Cell-Based therapy on recipient bone marrow niche in systemic lupus erythematosus. Int J Mol Sci, 2022. 23(7).

Heidari F, et al. 3D construct of hydroxyapatite/zinc oxide/palladium nanocomposite scaffold for bone tissue engineering. J Mater Sci Mater Med. 2020;31(10):85.

Article  CAS  PubMed  Google Scholar 

Shakir M, et al. Nano-hydroxyapatite/chitosan-starch nanocomposite as a novel bone construct: synthesis and in vitro studies. Int J Biol Macromol. 2015;80:282–92.

Article  CAS  PubMed  Google Scholar 

Shi Y, et al. Role of myeloid early endothelial progenitor cells in bone formation and osteoclast differentiation in tissue construct based on hydroxyapatite poly(ester-urethane) scaffolds. J Orthop Res. 2016;34(11):1922–32.

Article  CAS  PubMed  Google Scholar 

Taylor D, Hazenberg JG, Lee TC. Living with cracks: damage and repair in human bone. Nat Mater. 2007;6(4):263–8.

Article  CAS  PubMed  Google Scholar 

Singh T, et al. The critical role of bisphosphonates to target bone cancer metastasis: an overview. J Drug Target. 2015;23(1):1–15.

Article  CAS  PubMed  Google Scholar 

Tassone P, et al. Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy. Curr Cancer Drug Targets. 2009;9(7):854–70.

Article  CAS  PubMed  Google Scholar 

Lorusso L, et al. Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates. J Endocrinol Invest. 2021;44(12):2557–66.

Article  CAS